Cargando…
The kidney, subclinical thyroid disease and cardiovascular outcomes in older patients
OBJECTIVE: Thyroid hormones have been implicated to play a role in cardiovascular disease, along with studies linking thyroid hormone to kidney function. The aim of this study is to investigate whether kidney function modifies the association of subclinical thyroid dysfunction and the risk of cardio...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993270/ https://www.ncbi.nlm.nih.gov/pubmed/31846431 http://dx.doi.org/10.1530/EC-19-0502 |
_version_ | 1783492995680567296 |
---|---|
author | Zijlstra, L E van Velzen, D M Simsek, S Mooijaart, S P van Buren, M Stott, D J Ford, I Jukema, J W Trompet, S |
author_facet | Zijlstra, L E van Velzen, D M Simsek, S Mooijaart, S P van Buren, M Stott, D J Ford, I Jukema, J W Trompet, S |
author_sort | Zijlstra, L E |
collection | PubMed |
description | OBJECTIVE: Thyroid hormones have been implicated to play a role in cardiovascular disease, along with studies linking thyroid hormone to kidney function. The aim of this study is to investigate whether kidney function modifies the association of subclinical thyroid dysfunction and the risk of cardiovascular outcomes. METHODS: In total, 5804 patients were included in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). For the current analysis, 426 were excluded because of overt thyroid disease at baseline or 6 months, 266 because of inconsistent thyroid function at baseline and 6 months, 294 because of medication use that could influence thyroid function, and 16 because of missing kidney or thyroid values. Participants with normal fT4 were classified, based on TSH both at inclusion and 6 months, into three groups: subclinical hypothyroidism (TSH >4.5 mIU/L); euthyroidism (TSH = 0.45–4.5 mIU/L); and subclinical hyperthyroidism (TSH <0.45 mIU/L). Strata of kidney function were made based on estimated glomerular filtration rate into three clinically relevant groups: <45, 45–60, and >60 mL/min/1.73 m(2). The primary endpoint consists of death from coronary heart disease, non-fatal myocardial infarction and (non)fatal stroke. RESULTS: Mean age was 75.3 years, and 49.0% patients were male. Mean follow-up was 3.2 years. Of all participants, 109 subjects (2.2%) had subclinical hypothyroidism, 4573 (94.0%) had euthyroidism, and 182 (3.7%) subclinical hyperthyroidism. For patients with subclinical hypothyroidism, euthyroidism, and subclinical hyperthyroidism, primary outcome occurred in 9 (8.3%), 712 (15.6%), and 23 (12.6%) patients, respectively. No statistically significant relationship was found between subclinical thyroid dysfunction and primary endpoint with adjusted hazard ratios of 0.51 (0.24–1.07) comparing subclinical hyperthyroidism and 0.90 (0.58–1.39) comparing subclinical hypothyroidism with euthyroidism. Neither was this relationship present in any of the strata of kidney function, nor did kidney function interact with subclinical thyroid dysfunction in the association with primary endpoint (P interaction = 0.602 for subclinical hyperthyroidism and 0.388 for subclinical hypothyroidism). CONCLUSIONS: In this secondary analysis from PROSPER, we found no evidence that the potential association between thyroid hormones and cardiovascular disease is modified by kidney function in older patients with subclinical thyroid dysfunction. |
format | Online Article Text |
id | pubmed-6993270 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-69932702020-02-03 The kidney, subclinical thyroid disease and cardiovascular outcomes in older patients Zijlstra, L E van Velzen, D M Simsek, S Mooijaart, S P van Buren, M Stott, D J Ford, I Jukema, J W Trompet, S Endocr Connect Research OBJECTIVE: Thyroid hormones have been implicated to play a role in cardiovascular disease, along with studies linking thyroid hormone to kidney function. The aim of this study is to investigate whether kidney function modifies the association of subclinical thyroid dysfunction and the risk of cardiovascular outcomes. METHODS: In total, 5804 patients were included in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). For the current analysis, 426 were excluded because of overt thyroid disease at baseline or 6 months, 266 because of inconsistent thyroid function at baseline and 6 months, 294 because of medication use that could influence thyroid function, and 16 because of missing kidney or thyroid values. Participants with normal fT4 were classified, based on TSH both at inclusion and 6 months, into three groups: subclinical hypothyroidism (TSH >4.5 mIU/L); euthyroidism (TSH = 0.45–4.5 mIU/L); and subclinical hyperthyroidism (TSH <0.45 mIU/L). Strata of kidney function were made based on estimated glomerular filtration rate into three clinically relevant groups: <45, 45–60, and >60 mL/min/1.73 m(2). The primary endpoint consists of death from coronary heart disease, non-fatal myocardial infarction and (non)fatal stroke. RESULTS: Mean age was 75.3 years, and 49.0% patients were male. Mean follow-up was 3.2 years. Of all participants, 109 subjects (2.2%) had subclinical hypothyroidism, 4573 (94.0%) had euthyroidism, and 182 (3.7%) subclinical hyperthyroidism. For patients with subclinical hypothyroidism, euthyroidism, and subclinical hyperthyroidism, primary outcome occurred in 9 (8.3%), 712 (15.6%), and 23 (12.6%) patients, respectively. No statistically significant relationship was found between subclinical thyroid dysfunction and primary endpoint with adjusted hazard ratios of 0.51 (0.24–1.07) comparing subclinical hyperthyroidism and 0.90 (0.58–1.39) comparing subclinical hypothyroidism with euthyroidism. Neither was this relationship present in any of the strata of kidney function, nor did kidney function interact with subclinical thyroid dysfunction in the association with primary endpoint (P interaction = 0.602 for subclinical hyperthyroidism and 0.388 for subclinical hypothyroidism). CONCLUSIONS: In this secondary analysis from PROSPER, we found no evidence that the potential association between thyroid hormones and cardiovascular disease is modified by kidney function in older patients with subclinical thyroid dysfunction. Bioscientifica Ltd 2019-12-17 /pmc/articles/PMC6993270/ /pubmed/31846431 http://dx.doi.org/10.1530/EC-19-0502 Text en © 2020 The authors http://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Research Zijlstra, L E van Velzen, D M Simsek, S Mooijaart, S P van Buren, M Stott, D J Ford, I Jukema, J W Trompet, S The kidney, subclinical thyroid disease and cardiovascular outcomes in older patients |
title | The kidney, subclinical thyroid disease and cardiovascular outcomes in older patients |
title_full | The kidney, subclinical thyroid disease and cardiovascular outcomes in older patients |
title_fullStr | The kidney, subclinical thyroid disease and cardiovascular outcomes in older patients |
title_full_unstemmed | The kidney, subclinical thyroid disease and cardiovascular outcomes in older patients |
title_short | The kidney, subclinical thyroid disease and cardiovascular outcomes in older patients |
title_sort | kidney, subclinical thyroid disease and cardiovascular outcomes in older patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993270/ https://www.ncbi.nlm.nih.gov/pubmed/31846431 http://dx.doi.org/10.1530/EC-19-0502 |
work_keys_str_mv | AT zijlstrale thekidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients AT vanvelzendm thekidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients AT simseks thekidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients AT mooijaartsp thekidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients AT vanburenm thekidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients AT stottdj thekidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients AT fordi thekidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients AT jukemajw thekidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients AT trompets thekidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients AT zijlstrale kidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients AT vanvelzendm kidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients AT simseks kidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients AT mooijaartsp kidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients AT vanburenm kidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients AT stottdj kidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients AT fordi kidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients AT jukemajw kidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients AT trompets kidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients |